Human pluripotent stem cells (hPSCs), i.e. human embryonic stem cells and human induced pluripotent stem cells, are able to self-renew and differentiate into multiple cell types. Because of these abilities, numerous attempts have been made to utilize hPSCs in regenerative medicine/cell therapy. hPSCs are, however, also tumorigenic, that is, they can give rise to the progressive growth of tumor nodules in immunologically unresponsive animals. Therefore, assessing and managing the tumorigenicity of all final products is essential in order to prevent ectopic tissue formation, tumor development, and/or malignant transformation elicited by residual pluripotent stem cells after implantation. No detailed guideline for the tumorigenicity testing of hPSC-derived products has yet been issued for regenerative medicine/cell therapy, despite the urgent necessity. Here, we describe the current situations and issues related to the tumorigenicity testing of hPSC-derived products and we review the advantages and disadvantages of several types of tumorigenicity-associated tests. We also refer to important considerations in the execution and design of specific studies to monitor the tumorigenicity of hPSC-derived products.
INTRoducTIoN
Pluripotent stem cells, such as embryonic stem cells (EScs) and induced pluripotent stem cells (iPScs), have two abilities: 1) pluripotency, which is the ability to differentiate into a variety of cells, and 2) self-renewal, which is the ability to undergo numerous cell division cycles while maintaining their cellular identity. Because of these two characteristics, they are expected to provide new sources for the robust and continuous production of a variety of cells and tissues for use in regenerative medicine/cell therapy. Additionally, human iPScs (hiPScs) offer a possible solution to the ethical problems and immune rejection of cell products derived from human EScs (hEScs), thus creating novel avenues for individual patientspecific cell therapy. As a practical example of therapy using hESC-based products, the world's first clinical trial started in spinal cord patients in the united States in 2011. other clinical trials have also been conducted with retinal pigment epithelial (RPE) cells derived from hEScs to treat patients with dry age-related macular degeneration (AMd) and Stargardt's macular dystrophy by Advanced cell Technology.
1) Following Yamanaka's establishment of hiPScs in 2007, new innovations in regenerative medicine/cell therapy have been made that relate to cell substrates, manufacturing materials, and application methods. As one of the promising seeds for practical use in regenerative medicine/cell therapy, the clinical application of hiPSc-derived RPE cells is expected to start in 2013 in Japan for wet AMd patients.
For the proper development of hPSc-derived products, it is essential to assess their risk and to study their quality and safety. In this review, we place a particular focus on the current situations and issues related to the evaluation of tumorigenicity, which is one of the potential concerns in an attempt to conduct clinical research on hPSc-derived products.
ThE TuMoRIgENIcITY oF huMAN PluRIPo-TENT STEM cEllS
Tumorigenicity is defined as the capacity of a cell population inoculated into an animal model to produce a tumor by proliferation at the site of inoculation and/or at a distant site by metastasis.
2) undifferentiated hPScs have the ability to form teratoma in animals, and this is ascribed to their pluripotency. 3) In general, to demonstrate the pluripotency of established cells, they are injected into immunodeficient mice, e.g., nude mice, to form spontaneous teratomas. Teratomas are defined as tumors of multiple lineages containing tissue derived from the three germ layers (i.e., endoderm, mesoderm, and ectoderm). hPScs are tumorigenic and differ greatly from somatic cells and somatic stem cells in terms of tumorigenic potential. 4) Residual pluripotent cells in hPSc-derived products have the ability to initiate ectopic tissue formation, tumor development, and/or malignant transformation.
INTERNATIoNAl guIdElINES oF TuMoRIgENIcITY STudIES
At present, the World health organization (Who) TRS 878 guideline, titled, "Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks," 2, 5) is the only international guideline addressing tumorigenicity studies. The International conference on harmonization's "Ich guideline Q5d: derivation and characterisation of cell Substrates used for Production of Biotechnological/Biological Products" also cited the tumorigenicity tests of the Who TRS 878 guideline. These guidelines provide documented study design advice and general principles for tumorigenicity studies. Several in vitro test systems, such as cell growth in soft agar and muscle organ culture, have been explored as alternatives to in vivo tests for tumorigenicity 6) ; however, as a result of technical difficulties, the correlations with in vivo tests have not yet been clearly proved. Therefore, in the Who TRS 878, in vivo tests remain the standard for assessing tumorigenicity. Simply put, the model protocol of the in vivo tumorigenicity test in the Who TRS 878 is that 10 7 animal cells are administrated to 10 nude mice and observed for 3 to 16 weeks; hela cells are recommended as the positive control reference preparation. Applying this test to hPSc-based cell therapy products, we must learn about its coverage and purpose. The in vivo tumorigenicity test proposed in Who TRS 878 covers cells used to manufacture biological products but not cells transplanted into patients. Its purpose is to examine the tumorigenic phenotype range, from non-tumorigenic to weakly-or highly tumorigenic, of the cell banks, but not to detect the slightly contaminated tumorigenic cells in hPSc-derived products. The Who TRS 878 also requires the master or working cell bank to check the tumorigenicity whenever cultured for predetermined passage times. Who TRS 878 has therefore not directly addressed the tumorigenicity of hPSc-derived products. Importantly, the tumorigenicity described in Who TRS 878 is not a direct risk index for humans but that estimated by animal testing, which examines tumor formation at transplanted sites and metastasis at remote sites.
AlTERNATIVE APPlIcATIoN oF Who TRS 878 To hPSc-dERIVEd PRoducTS
As mentioned above, one of the risks of hPSc-derived products is the possibility of tumor formation following transplantation. To ensure safety, the tumorigenicity of hPSc-derived products must be evaluated to identify undifferentiated and/or abnormal cells that might exist in minute quantities in final products. It should be noted that the tumorigenicity of final products is clearly different from the tumorigenicity of the cell bank of serially passaged cell lines defined as cell substrates in Who TRS 878. however, we must consider how the Who TRS 878 protocol of tumorigenicity testing should be applied to hPSc-derived products because the Who TRS878 guideline is the only one that directly addresses tumorigenicity studies. First, we understand the grounds of the Who TRS 878 tumorigenicity test protocol to require administratation of 10 7 cells to nude mice. Tumor-producing doses at the 50% endpoint (TPd 50 ) (the number of cells required for tumor development with 50% probability) are used as units of tumorigenic phenotypes. 
AVAIlABIlITY oF hIghlY IMMuNodEFIcIENT MIcE
To detect slightly contaminated tumorigenic cells in hPScderived products, several new generations of severely immunodeficient animal models are now available. Rag2-γc doubleknockout (dKo) mice, 8) Nod/ScId/γc null (Nog) mice, 9) and Nod/ScId/Il-2rgKo (NSg) mice 10) are reported to be T, B, and NK cell-defective and to show high engraftment rates of human cells and tissues compared with traditional nude (T cell-defective) mice. 11, 12) using these severe combined immunodeficient mouse lines, which are likely to be useful for sensitive in vivo tumorigenicity tests, the small amount of residual tumorigenic cells in the hPSc-derived products could be detected. Since scientific risk assessment needs to standardize the tumorigenicity evaluation of hPSc-derived products, the following points should be taken into consideration in the development of in vivo tumorigenicity tests: (a) validation of the limit of detection, sensitivity, and precision, (b) positive and negative control selection, (c) number of tested cells, (d) test duration, (e) route/method of administration, and (f) comparison with nude mouse.
IN VITRo TuMoRIgENIcITY-ASSocIATEd TESTS
Some tests are indicated to detect tumorigenic cells contaminating cell populations in vitro. Table 1 summarizes the advantages and disadvantages of the tests associated with product tumorigenicity. The soft agar colony formation assay is a conventional method to monitor anchorage-independent growth, and is considered the most appropriate in vitro assay to detect the malignant transformation of cells. 6) Previous reports have shown that hPScs undergo apoptosis when dissociated into single cells. 13) This test requires the scattering of cells and their enclosure in agar so it may be difficult to utilize it for tests of hPSc-derived product tumorigenicity. Flow cytometry and quantitative reverse transcription polymerase chain reaction (qRT-PcR) tests were found to be able to detect a trace amount of undifferentiated cells. The advantage of the flow cytometry test is that it can be used to identify undifferentiated cells. unfortunately, the results are greatly affected by gating, and only the cells expressing the marker proteins are detectable. The advantages of qRT-PcR are its rapidity, quantitative nature, and high sensitivity. Its disadvantage is that only the cells expressing the marker gene are detectable. our previous report demonstrated that the soft agar colony formation assay is unable to detect hiPScs, even in the presence of a Rho-associated protein kinase (RocK) inhibitor that permits survival of dissociated hiPSCs/hESCs. The flow cytometry test using anti-TRA-1-60 antibody has detected 0.1% undifferentiated hiPScs spiked in primary RPE cells. The qRT-PCR method with a specific probe and primers has been found to detect a trace amount of lin28 mRNA, which is equivalent to that present in a mixture of a single hiPSc and 5×10 4 RPE cells. 14) As tumorigenic cells are commonly highly proliferative and immortalized, observation of the cell growth rate by culturing for a limited period also seems to be useful to detect rapidly growing contaminated immortalized cells. If combinations of these in vitro tumorigenicity-associated tests do not demonstrate the existence of both undifferentiated and immortalized cells, the tumorigenic potential of final products can be considered extremely low. More importantly, the validity of advancing to clinical trials should be confirmed for each product and judged by the following points: (a) methods of cell inoculum, (b) sites of injection, (c) risk management plans, (d) results from in vivo tumorigenicity tests.
coNcluSIoN ANd FuTuRE PRoSPEcTS
No guideline for the tumorigenicity testing of cell-/ tissue-derived products, including hPSc-derived products, has been issued. Because the subject and purpose described in Who TRS 878 are not suitable for hPSc-derived products, the direct application of the Who TRS 878 tumorigenicity test to hPSc-derived products is unreasonable. Tumorigenicity studies for hPSc-based products should examine (a) the existence of residual undifferentiated pluripotent cells, (b) the existence of tumorigenic transformants, and (c) whether the transplant forms tumor in microenvironments at the site of transplantation. As a countermeasure, highly sensitive in vivo tumorigenicity tests using severely immunodeficient mice may be a viable option. We now address the current problems with the development and standardization of in vivo tumorigenicity tests for hPSc-derived products.
Safety assessments of hPSc-derived products must choose among various tumorigenicity tests, considering the limitations of each. The overall safety of each product should be estimated on the basis of the results of an appropriate set of tumorigenicity tests. The following points should also be taken into account in order to decide on the items to evaluate: (a) properties of the raw materials, (b) properties of the products, (c) target diseases, and (d) risk management. of course, the results/assessments of even the most appropriate tumorigenicity tests cannot guarantee safety in humans. After understanding the limitation of each tumorigenicity test, we should develop a risk assessment and risk management plan and obtain informed patient consent. 
